pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

669 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT785Endpoints586BioPharma Dive224onclive165BioSpace60Fierce Biotech59raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage market
    Devoted Health’s revenue and membership declined in 2025 for the first time since it launched health plans for seniors seven years ago. It’s a sign the high-profile startup, helmed by former Athe…
    Endpoints · 3mo ago↗ source
  • Adaptyv Bio reveals latest results in protein design competition
    RIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing proteins. Its latest competition, presented Monday at a…
    Endpoints · 3mo ago↗ source
  • Lilly strikes second partnership this year for recombinase-based gene editing
    Decades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because they were hardwire…
← prev
page 26 of 27
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 3mo ago
↗ source
  • Galapagos spinout Coultreon raises $125M for new take on SIK inhibition
    Coultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the burgeoning pipeline-in-a-pill approach to autoimmune disea…
    Endpoints · 3mo ago↗ source
  • Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending
    Novartis CEO Vas Narasimhan said the Swiss company is “very disappointed” by Germany’s plan to shave off more than €60 billion in healthcare costs that would affect pharma sales. Germany wants to…
    Endpoints · 3mo ago↗ source
  • Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
    Obesity patients taking the weight loss injection being developed by Boehringer Ingelheim lost nearly 17% of their weight after about a year and a half, the company said Tuesday. The results are mo…
    Endpoints · 3mo ago↗ source
  • Erasca reports RAS cancer drug data after legal threat from Revolution
    After a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could prompt a legal showdown b…
    Endpoints · 3mo ago↗ source
  • Revolution Medicines threatens to sue Erasca over patent, efficacy claims
    Earlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, Erasca said it had received a legal threat from Revolution Medicines' lawyers…
    Endpoints · 3mo ago↗ source
  • Utah doctors demand suspension of Doctronic AI program
    Members of Utah’s medical licensing board have called for the suspension of a temporary program allowing a startup to use AI to refill prescription medications. The startup, Doctronic, struck an…
    Endpoints · 3mo ago↗ source
  • Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next
    Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous…
    Endpoints · 3mo ago↗ source
  • Thermo Fisher sells microbiology biz; Ligand to buy XOMA
    Thermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part of its specialt…
    Endpoints · 3mo ago↗ source
  • Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
    Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental dr…
    Endpoints · 3mo ago↗ source
  • Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
    Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as
    Endpoints · 3mo ago↗ source
  • Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial
    A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the in…
    Endpoints · 3mo ago↗ source
  • Intellia's in vivo CRISPR therapy first to succeed in Phase 3
    An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…
    Endpoints · 3mo ago↗ source
  • Veradermics wins at growing hair with oral Rogaine in first key test as a public company
    Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern ha…
    Endpoints · 3mo ago↗ source
  • AI biotech Fathom raises $47M Series A, renames from Atommap
    In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his eponymous research company. Huafe…
    Endpoints · 3mo ago↗ source
  • Sun Pharma to buy Organon for $11.75B in major portfolio expansion
    Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in 2021. The all-cash deal came in at $14 per share ...
    Endpoints · 3mo ago↗ source
  • Investment in UK biotechs shows early signs of recovery, report says
    After a lull in mid-2025, investment in UK biotechs appears to be picking up, according to data from the UK trade group the BioIndustry Association. In the first quarter of 2026, total equity fun…
    Endpoints · 3mo ago↗ source
  • Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more
    Welcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards, which recognize excellence in B2B journalism. The ...
    Endpoints · 3mo ago↗ source
  • FDA unveils three psychedelic-focused commissioner vouchers
    The FDA said Friday it has issued new fast-track vouchers to three psychedelic companies, and its selections have come as a “surprise” to Wall Street. In an unusual move, the agency didn’t name t…
    Endpoints · 3mo ago↗ source
  • Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug
    Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public…
    Endpoints · 3mo ago↗ source
  • Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
    Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain f…
    Endpoints · 3mo ago↗ source
  • Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy
    The new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drug…
    Endpoints · 3mo ago↗ source
  • Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
    Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European M…
    Endpoints · 3mo ago↗ source